RSV Seasonal Vaccine Introduction and Growth Strategy

A focused global biopharma company with momentum and bold ambitions GSK Strategy focused on prevention and treatment to get ahead of disease together World leader in infectious disease with a broader pipeline based on science of the immune system Highly attractive medium-term¹ target for sales and adjusted operating profit CAGR² Confident in ability to sustain profitable growth through the decade and beyond GSK 1. Medium-term is 2021-2026, excluding COVID-19 solutions 2. At constant exchange rates (CER) 30 30

View entire presentation